Sorrento Therapeutics is a biopharmaceutical that develops therapies for various diseases, including cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. They use targeted delivery modalities and drug delivery technology to provide cancer therapeutic and other treatments. The company has several clinical programs in development, collaborations with other biopharmaceuticals, and has developed SEMDEXA, SP-103, SP-104, and ZTlido for various treatments.